The need for diagnosis, treatment and prevention of AITD is also due to the need to prevent concomitant diseases, including disorders of the cardiovascular system, hypercholesterolemia, atrial fibrillation, encephalopathy, others autoimmune diseases ( Cellular and humoral immunity in the pathogenesis of AITD In addition to genetic, cellular and humoral immune mechanisms, loss of immune tolerance to thyroid autoantigens is the basis for the development of AITD
The GLP-1 receptor agonists cardiovascular benefits are believed to stem from their effects in reducing dysfunctional body fat cells, improving glycemic control, reducing blood pressure and inflammation, and perhaps improving vascular endothelial function and plaque stability
Xie A, Hanif S, Ouyang J, Tang Z, Kong N, Kim NY, et al
Pasternak, V